Recommendations for the treatment of ulcerative colitis with infliximab: A gastroenterology expert group consensus
Authors:
- Walter ReinischWRWalter Reinisch
- Gert Van AsscheGAGert Van Assche
- Ragnar BefritsRBRagnar Befrits
- William ConnellWCWilliam Connell
- Geert D'HAensGDGeert D'HAens
- Subrata GhoshSGSubrata Ghosh
- Pierre MichettiPMPierre Michetti
- Thomas OchsenkühnTOThomas Ochsenkühn
- Remo PanaccioneRPRemo Panaccione
- Stefan SchreiberSSStefan Schreiber
- Mark S. SilverbergMSMark S. Silverberg
- Dario SorrentinoDSDario Sorrentino
- 1 March 2012
- journal article
- review article
- Published by Oxford University Press (OUP) in Journal of Crohn's and Colitis
- Vol. 6 (2) , 248-258
Abstract
Infliximab is currently the only biologic approved for treatment of adults with moderate to severe, active ulcerative colitis (UC) unresponsive to conventional therapies. It rapidly controls symptoms, induces and sustains steroid-free remission, stimulates mucosal healing, and reduces serious complications. Although infliximab tends to be reserved for patients with severe disease, it may be even more beneficial for moderate disease earlier in the disease course. Therefore, it is important to identify which patients are candidates for infliximab therapy. A collaborative Delphi survey was used to obtain consensus on use of biologic therapy in patients with UC from an expert panel of 12 gastroenterologists with substantial experience using infliximab in clinical practice and clinical trials. The panel also addressed issues that influence the use of infliximab in UC, including its potential as an alternative to surgery. The panel agreed that: (1) it is necessary to adopt additional treatment goals beyond symptom control, i.e., complete mucosal healing, steroid-free remission, improved QoL, and reduced long-term complications; (2) it may be possible to achieve these treatment goals with infliximab, especially if it is used earlier in the course of UC; and (3) infliximab should be offered as an alternative to surgery in patients being considered for colectomy. The panel also agreed on factors for identifying candidates for infliximab therapy (e.g., persistently active UC, steroid-dependent/refractory disease, and high C-reactive protein). This consensus statement provides useful and practical information on how to achieve evolving treatment goals with infliximab in moderate to severe UC.Keywords
This publication has 32 references indexed in Scilit:
- Outcome of pregnancy in women with inflammatory bowel disease treated with antitumor necrosis factor therapyInflammatory Bowel Diseases, 2011
- Safety of infliximab use during pregnancyReproductive Toxicology, 2011
- Anti-TNF therapies and pregnancy: outcome of 130 pregnancies in the British Society for Rheumatology Biologics RegisterAnnals of the Rheumatic Diseases, 2011
- High intra-uterine exposure to infliximab following maternal anti-TNF treatment during pregnancyAlimentary Pharmacology & Therapeutics, 2011
- Advanced Age Is an Independent Risk Factor for Severe Infections and Mortality in Patients Given Anti–Tumor Necrosis Factor Therapy for Inflammatory Bowel DiseaseClinical Gastroenterology and Hepatology, 2011
- Infliximab, Azathioprine, or Combination Therapy for Crohn's DiseaseNew England Journal of Medicine, 2010
- Clinical course during the first 10 years of ulcerative colitis: results from a population-based inception cohort (IBSEN Study)Scandinavian Journal of Gastroenterology, 2009
- Exposing the Weaknesses: A Systematic Review of Azathioprine Efficacy in Ulcerative ColitisDigestive Diseases and Sciences, 2007
- Drug Insight: anti-tumor necrosis factor therapy for inflammatory arthropathies during reproduction, pregnancy and lactationNature Clinical Practice Rheumatology, 2007
- Infliximab for Induction and Maintenance Therapy for Ulcerative ColitisNew England Journal of Medicine, 2005